- Trial Phase
- Phase 3 (completed for prostate cancer); Phase 2 (pancreatic cancer, completed); Phase 3 AURORA (NSCLC, just initiated J
- Time to Market
- If the BLA is submitted in Q4 2026 and accepted, a potential FDA decision on CAN-2409 for prostate cancer could come in late 2027 to early 2028 — a standard 10-12 month review cycle. Commercial launch could follow shortly after approval.
- Why 7/10
- The next hard catalyst is the BLA submission for CAN-2409 in localized prostate cancer, expected in Q4 2026 (~3-6 months out). CAN-2409 is Candel's lead and nearly sole value driver. While a submission is not as binary as a PDUFA decision, it is a major derisking milestone that will confirm the completeness of the Phase 3 data package and trigger a ~10-12 month FDA review clock, likely driving substantial price movement.
Watch for the BLA submission in Q4 2026 — actual filing will confirm the Phase 3 package is FDA-ready and start the review clock. Key risk: dilution risk is real (company has used both debt and equity financing) and the stock already trades near 52-week highs. The Phase 3 AURORA trial in NSCLC (just initiated June 30, 2026) is a longer-term pipeline driver but won't read out for years.
Price Chart
Executive Summary
CAN-2409 (aglatimagene besadenovec) is Candel Therapeutics' lead and most advanced immunotherapy — a viral immunotherapy that trains the immune system to fight solid tumors. It has already succeeded in a pivotal Phase 3 trial in localized prostate cancer (745 patients, HR 0.70, p=0.0155 for disease-free survival), with results published in The Lancet Oncology. The company plans to submit a Biologics License Application (BLA) in Q4 2026, making it a pre-revenue, pre-approval biotech with a major near-term catalyst. The drug also showed striking Phase 2 survival data in pancreatic cancer (31.4 vs 12.5 months median OS) and NSCLC. Candel has secured a $130M term loan facility and drawn $50M, giving it runway into early 2028. The stock has strong institutional backing (Fidelity, Baker Bros, RTW Investments) and a mean analyst price target of ~$20 (roughly 2x current levels).
How It Works
CAN-2409 is a modified, harmless cold virus (adenovirus) that is injected directly into a patient's tumor. It carries a gene that makes tumor cells produce a specific enzyme. When the patient also takes a standard anti-herpes pill (valacyclovir), that enzyme converts the pill into a toxin inside cancer cells, killing them in a way that "teaches" the immune system to recognize and attack the cancer throughout the body. It's like a targeted training camp for the immune system.
Trial Status
The pivotal Phase 3 trial (NCT01436968) in 745 men with intermediate-to-high risk localized prostate cancer met its primary endpoint in December 2024, showing a statistically significant 30% reduction in risk of recurrence or death (HR 0.70, p=0.0155). Results were published in The Lancet Oncology in June 2026. A Phase 2 pancreatic cancer trial showed median overall survival of 31.4 months vs 12.5 months for standard of care. The Phase 2 NSCLC trial showed encouraging survival in patients who progressed on checkpoint inhibitors, supporting the initiation of the global Phase 3 AURORA trial announced June 30, 2026.
The Two-Sided Case
Upcoming Catalysts
- Q4 2026: BLA submission for CAN-2409 in localized prostate cancer — the single biggest near-term value driver
- FDA acceptance of BLA filing and PDUFA date assignment (likely ~60 days post-submission)
- Phase 3 AURORA trial (NSCLC) enrollment updates — just initiated June 30, 2026 across 150+ sites
- Potential CAN-3110 (pipeline follow-on) updates in high-grade glioma — Phase 1b data anticipated
- Commercial launch preparation updates including commercial team buildout and pricing strategy
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Candel Therapeutics Press Release CADL ·Originating report